Jounce Therapeutics, Inc. (NASDAQ: JNCE) today presented preliminary data from its ongoing Phase 1/2 ICONIC trial, an adaptive design, open-label ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Management Comments

Cowen Downgrades Jounce Therapeutics (JNCE) to Market PerformJune 5, 2018 5:42 AM Baird Remains Positive on Jounce Therapeutics (JNCE)June 4, 2018 8:08 AM JPMorgan Downgrades Jounce Therapeutics (JNCE) to NeutralJune 4, 2018 5:30 AM Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced CancersJune 2, 2018 4:00 PM